Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update [Yahoo! Finance]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Ongoing Pivotal Phase 2 ALPHA3 Trial Advancing with Site Activation and Patient Enrollment Lymphodepletion Selection and Futility Analysis Anticipated Around Mid-2025 Primary EFS Data Expected Around YE 2026 with Potential BLA Submission in 2027 ALLO-329 in Autoimmune Disease (AID) Secured Investigational New Drug (IND) FDA Clearance for the RESOLUTION Basket Trial in Rheumatology Trial Initiation Targeted for Mid-2025; Proof-of-Concept Data Expected Around YE 2025 ALLO-316 in Renal Cell Carcinoma (RCC) Presented Positive Phase 1 Data Highlighting Meaningful Response Rates in Patients with Advanced Renal Cell Carcinoma and the Potential of the CD70 Dagger ® Technology to Promote Robust CAR T Cell Expansion and Persistence Phase 1b Expansion Cohort Enrollment Completed with Data Expected Mid-2025 Ended Q4 2024 with $373.1 Million in Cash, Cash Equivalents and Inves
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and SclerodermaGlobeNewswire
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at HC Wainwright from $9.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock.MarketBeat
ALLO
Earnings
- 3/13/25 - Beat
ALLO
Sec Filings
- 4/30/25 - Form DEFA14A
- 4/30/25 - Form ARS
- 4/30/25 - Form DEF
- ALLO's page on the SEC website